G
Galit Kleiner-Fisman
Researcher at University of Toronto
Publications - 35
Citations - 7746
Galit Kleiner-Fisman is an academic researcher from University of Toronto. The author has contributed to research in topics: Parkinson's disease & Deep brain stimulation. The author has an hindex of 23, co-authored 35 publications receiving 6359 citations. Previous affiliations of Galit Kleiner-Fisman include University Health Network & University of Pennsylvania.
Papers
More filters
Journal ArticleDOI
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results.
Christopher G. Goetz,Barbara C. Tilley,Stephanie R. Shaftman,Glenn T. Stebbins,Stanley Fahn,Pablo Martinez-Martin,Werner Poewe,Cristina Sampaio,Matthew B. Stern,Richard Dodel,Bruno Dubois,Robert G. Holloway,Joseph Jankovic,Jaime Kulisevsky,Anthony E. Lang,Andrew J. Lees,Sue Leurgans,Peter A. LeWitt,David L. Nyenhuis,C. Warren Olanow,Olivier Rascol,Anette Schrag,Jeanne A. Teresi,Jacobus J. van Hilten,Nancy R. LaPelle,Pinky Agarwal,Saima Athar,Yvette Bordelan,Helen Bronte-Stewart,Richard Camicioli,Kelvin L. Chou,Wendy Cole,Arif Dalvi,Holly Delgado,Alan Diamond,Jeremy P.R. Dick,John E. Duda,Rodger J. Elble,Carol Evans,V. G. H. Evidente,Hubert H. Fernandez,Susan H. Fox,Joseph H. Friedman,Robin D. Fross,David A. Gallagher,Deborah A. Hall,Neal Hermanowicz,Vanessa K. Hinson,Stacy Horn,Howard I. Hurtig,Un Jung Kang,Galit Kleiner-Fisman,Olga Klepitskaya,Katie Kompoliti,Eugene C. Lai,Maureen L. Leehey,Iracema Leroi,Kelly E. Lyons,Terry McClain,Steven W. Metzer,Janis M. Miyasaki,John C. Morgan,Martha Nance,Joanne Nemeth,Rajesh Pahwa,Sotirios A. Parashos,Jay S. Schneider,Kapil D. Sethi,Lisa M. Shulman,Andrew Siderowf,Monty Silverdale,Tanya Simuni,Mark Stacy,Robert Malcolm Stewart,Kelly L. Sullivan,David M. Swope,Pettaruse M. Wadia,Richard Walker,Ruth H. Walker,William J. Weiner,Jill Wiener,Jayne R. Wilkinson,Joanna M. Wojcieszek,Summer C. Wolfrath,Frederick Wooten,Allen Wu,Theresa A. Zesiewicz,Richard M. Zweig +87 more
TL;DR: The combined clinimetric results of this study support the validity of the MDS‐UPDRS for rating PD.
Journal ArticleDOI
Subthalamic nucleus deep brain stimulation: Summary and meta-analysis of outcomes
Galit Kleiner-Fisman,Jan Herzog,David N. Fisman,Filippo Tamma,Kelly E. Lyons,Rajesh Pahwa,Anthony E. Lang,Günther Deuschl +7 more
TL;DR: Synthesis of the available literature indicates that STN DBS improves motor activity and activities of daily living in advanced PD and provides an estimate of the magnitude of the treatment effects and emphasize the need for controlled and randomized studies.
Journal ArticleDOI
Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease
Galit Kleiner-Fisman,David N. Fisman,Elspeth Sime,Jean A. Saint-Cyr,Andres M. Lozano,Anthony E. Lang +5 more
TL;DR: In this group of patients with advanced PD who underwent bilateral DBS of the STN, sustained improvement in motor function was present a mean of 2 years after the procedure, and sustained reductions in drug requirements were also achieved.
Journal ArticleDOI
Deep brain stimulation: postoperative issues.
Günther Deuschl,Jan Herzog,Galit Kleiner-Fisman,Cynthia S. Kubu,Andres M. Lozano,Kelly E. Lyons,Maria C. Rodriguez-Oroz,Filippo Tamma,Alexander I. Tröster,Jerrold L. Vitek,Jens Volkmann,Valerie Voon +11 more
TL;DR: Answer to a series of questions developed to address all aspects of DBS postoperative management and decision‐making with a systematic overview of the literature are outlined.
Journal ArticleDOI
Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists.
Judit Horvath,Robin D. Fross,Galit Kleiner-Fisman,René Lerch,Hans Stalder,Suzanne Liaudat,William J. Raskoff,Keith Flachsbart,Harry Rakowski,Jean-Claude Pache,Pierre Burkhard,Anthony E. Lang +11 more
TL;DR: It is proposed that an assessment of cardiac function be performed before and in the course of a long‐term therapy with ergot derivative dopamine agonists, suggesting that the authors may well be facing a novel, yet unrecognized, complication of this class of agents.